Developers of biosimilars, medicines that are near-identical copies of biologic drugs, will no longer be required to conduct clinical trials to prove effectiveness.

FDA announces major reforms to streamline biosimilar approvals, potentially saving Americans billions on prescription drug costs by removing extra clinical trial requirements.

Dr. Mehmet Oz and Dr. Marty Makary touted that reducing steps for biosimilar approval will lower costs by increasing competition.

Xcellon Biologics will incorporate IntoCell’s OHPAS drug-linker system into its range of ADC development suites.

Connect Biopharma Holdings Limited ( CNTB) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases November 3, 2025 4:15 PM EST ...

Co., Ltd. (hereinafter referred to as "Sanyou Bio") and Shanghai ZJ Bio-Tech technology Co., Ltd. (hereinafter referred to as "Shanghai ZJ Bio-Tech") jointly announced the official signing of a ...

Researchers at McMaster University have discovered that the eyes may offer a powerful, non-invasive way to assess heart ...

All over the world people are ageing more rapidly and succumbing to diseases that typically affected the elderly. But there ...

Viridian seeks Priority Review for veligrotug, aiming for a potential mid-2026 commercial launch if approved. Global phase 3 ...

By restructuring a common chemotherapy drug, scientists increased its potency by 20,000 times. In a significant step forward ...

Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to ...

Learn how labman is advancing biologics manufacturing through AI-powered bioreactor technology, driving innovation in drug ...